Iqvia Holdings Inc (NYSE:IQV) Short Interest Down 12.4% in July

Iqvia Holdings Inc (NYSE:IQV) was the recipient of a significant decline in short interest in the month of July. As of July 31st, there was short interest totalling 2,474,900 shares, a decline of 12.4% from the June 30th total of 2,824,800 shares. Currently, 1.4% of the company’s shares are sold short. Based on an average daily volume of 1,270,000 shares, the days-to-cover ratio is currently 1.9 days.

Several research firms recently weighed in on IQV. Wells Fargo & Co lifted their price objective on Iqvia from $170.00 to $178.00 and gave the company an “outperform” rating in a report on Thursday, July 25th. Zacks Investment Research upgraded Iqvia from a “sell” rating to a “hold” rating in a report on Friday, May 3rd. William Blair restated an “outperform” rating on shares of Iqvia in a report on Wednesday, June 19th. Stifel Nicolaus lifted their price objective on Iqvia from $167.00 to $178.00 and gave the company a “buy” rating in a report on Wednesday, June 19th. Finally, TheStreet downgraded Iqvia from a “b” rating to a “c+” rating in a report on Wednesday, May 1st. Three equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and two have assigned a strong buy rating to the stock. Iqvia presently has a consensus rating of “Buy” and an average price target of $161.13.

Iqvia stock traded up $3.06 during trading hours on Friday, reaching $155.21. The stock had a trading volume of 830,995 shares, compared to its average volume of 1,264,131. The company has a market cap of $30.77 billion, a price-to-earnings ratio of 30.31, a PEG ratio of 1.91 and a beta of 0.88. The company has a debt-to-equity ratio of 1.72, a current ratio of 1.14 and a quick ratio of 1.14. The business’s 50 day moving average price is $157.81 and its 200-day moving average price is $144.08. Iqvia has a 52 week low of $104.90 and a 52 week high of $164.13.

Iqvia (NYSE:IQV) last announced its earnings results on Wednesday, July 24th. The medical research company reported $1.39 EPS for the quarter, topping the Zacks’ consensus estimate of $1.38 by $0.01. The business had revenue of $2.74 billion during the quarter, compared to the consensus estimate of $2.70 billion. Iqvia had a net margin of 2.31% and a return on equity of 15.95%. The firm’s revenue was up 6.7% on a year-over-year basis. During the same period in the previous year, the company posted $1.29 earnings per share. On average, sell-side analysts forecast that Iqvia will post 5.87 EPS for the current fiscal year.

In other news, insider Kevin C. Knightly sold 6,945 shares of the business’s stock in a transaction on Monday, July 29th. The shares were sold at an average price of $158.53, for a total transaction of $1,100,990.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Ari Bousbib sold 96,000 shares of Iqvia stock in a transaction dated Wednesday, June 19th. The shares were sold at an average price of $150.00, for a total value of $14,400,000.00. The disclosure for this sale can be found here. Insiders have sold 198,945 shares of company stock valued at $30,860,991 over the last three months. Insiders own 6.00% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the business. CWM LLC increased its holdings in shares of Iqvia by 63.4% during the second quarter. CWM LLC now owns 165 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 64 shares in the last quarter. C J Advisory Inc acquired a new position in shares of Iqvia during the first quarter valued at about $27,000. Baystate Wealth Management LLC acquired a new position in shares of Iqvia during the first quarter valued at about $27,000. Parkside Financial Bank & Trust increased its holdings in shares of Iqvia by 140.2% during the first quarter. Parkside Financial Bank & Trust now owns 209 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 122 shares in the last quarter. Finally, Capital Investment Advisory Services LLC increased its holdings in shares of Iqvia by 46.0% during the second quarter. Capital Investment Advisory Services LLC now owns 219 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 69 shares in the last quarter. Institutional investors and hedge funds own 92.29% of the company’s stock.

Iqvia Company Profile

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Further Reading: What are the benefits of investing in REITs?

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.